Results 221 to 230 of about 20,678 (258)
Some of the next articles are maybe not open access.
Wildagliptyna – wyjątkowy inhibitor DPP-4
Medycyna Faktów, 2022Wildagliptyna jest jedynym lekiem z grupy inhibitorów DPP-4, który stosuje się 2 razy dziennie. Chociaż nie przeprowadzono badania poświęconego bezpieczeństwu sercowo-naczyniowemu stosowania tego leku, to licznie opublikowane metaanalizy oraz badania obserwacyjne jednoznacznie potwierdziły bezpieczeństwo wildagliptyny w tym zakresie.
openaire +1 more source
DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
Archives of Pharmacal Research, 2016Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are an emerging class of antidiabetic drugs that constitutes approximately fifty percent of the market share of the oral hypoglycemic drugs. Its mechanism of action for lowering blood glucose is essentially via inhibition of the rapid degradation of incretin hormones, such as glucagon-like peptide ...
openaire +2 more sources
Inappropriate Use of DPP-4 Inhibitors
2014Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents for the treatment of type 2 diabetes. They have shown reduction of blood glucose, but potential impact on cardiovascular outcomes and long-term safety remain inconclusive. For that reasons DPP-4[for full text, please go to the a.m. URL]
Reichel, A +4 more
openaire +1 more source
How safe are DPP‐4 inhibitors?
Practical Diabetes, 2013AbstractAbstract.
Laura McCreight, Miles Fisher
openaire +1 more source
[DPP-4 inhibitors in nephropatics].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologiaThe use of glucose-lowering drugs in advanced stage diabetic nephropathic patients should be done very carefully. Some drugs are contraindicated or not recommended. The same insulin needs a dose reduction to avoid dangerous hypoglycemia. For some years the use of inhibitors of the DDP-4 has been approved in T2DM patients with CKD III and IV stage ...
Annamaria, Bruzzese +4 more
openaire +1 more source
[Once-weekly DPP-4 inhibitor].
Nihon rinsho. Japanese journal of clinical medicine, 2016Trelagliptin is the first once-weekly dipeptidyl peptidase-4(DPP-4) inhibitor in the world. Trelagliptin inhibits DPP-4 activity with lower drug concentration compared with other once- (or twice-) daily DPP-4 inhibitors in in vitro study. More than 70 % of DPP-4 activity is inhibited even 1 week after administration of trelagliptin administration in ...
Norio, Harada, Nobuya, Inagaki
openaire +1 more source
Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022Abdulsalam Alhalmi +2 more
exaly